Recent high throughput genomic studies have revealed several gene and pathway alterations associated with MIBC [5, 6], including PI3K/AKT/mTOR and ERK/MEK/RAS pathways as drivers of bladder cancer progression and potential targets for therapeutic interventions [3]. This evidence concerns the gene PIK3CA and urinary bladder cancer.